GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Landos Biopharma Inc (NAS:LABP) » Definitions » ROE %

Landos Biopharma (Landos Biopharma) ROE % : -70.48% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Landos Biopharma ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Landos Biopharma's annualized net income for the quarter that ended in Dec. 2023 was $-24.48 Mil. Landos Biopharma's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $34.73 Mil. Therefore, Landos Biopharma's annualized ROE % for the quarter that ended in Dec. 2023 was -70.48%.

The historical rank and industry rank for Landos Biopharma's ROE % or its related term are showing as below:

LABP' s ROE % Range Over the Past 10 Years
Min: -604.4   Med: -206.7   Max: -55.15
Current: -55.15

During the past 6 years, Landos Biopharma's highest ROE % was -55.15%. The lowest was -604.40%. And the median was -206.70%.

LABP's ROE % is ranked worse than
57.12% of 1362 companies
in the Biotechnology industry
Industry Median: -44.1 vs LABP: -55.15

Landos Biopharma ROE % Historical Data

The historical data trend for Landos Biopharma's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Landos Biopharma ROE % Chart

Landos Biopharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial - - -345.32 -68.07 -61.86

Landos Biopharma Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -50.34 -56.03 -34.75 -57.92 -70.48

Competitive Comparison of Landos Biopharma's ROE %

For the Biotechnology subindustry, Landos Biopharma's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Landos Biopharma's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Landos Biopharma's ROE % distribution charts can be found below:

* The bar in red indicates where Landos Biopharma's ROE % falls into.



Landos Biopharma ROE % Calculation

Landos Biopharma's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-21.935/( (39.131+31.791)/ 2 )
=-21.935/35.461
=-61.86 %

Landos Biopharma's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-24.476/( (37.664+31.791)/ 2 )
=-24.476/34.7275
=-70.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Landos Biopharma  (NAS:LABP) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-24.476/34.7275
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-24.476 / 0)*(0 / 40.635)*(40.635 / 34.7275)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.1701
=ROA %*Equity Multiplier
=N/A %*1.1701
=-70.48 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-24.476/34.7275
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-24.476 / -24.476) * (-24.476 / -26.44) * (-26.44 / 0) * (0 / 40.635) * (40.635 / 34.7275)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9257 * N/A % * 0 * 1.1701
=-70.48 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Landos Biopharma ROE % Related Terms

Thank you for viewing the detailed overview of Landos Biopharma's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Landos Biopharma (Landos Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 11239, Blacksburg, VA, USA, 24060
Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. It operates in one reportable segment of operations and manages.
Executives
Alka Batycky director C/O LANDOS BIOPHARMA, INC., P.O. BOX 11239, BLACKSBURG VA 24062
Perceptive Xontogeny Venture Fund Ii, Lp 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Roderick Wong 10 percent owner C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Fabio Cataldi officer: Chief Medical Officer C/O LANDOS BIOPHARMA, INC., PO BOX 11239, BLACKSBURG VA 24062
Gregory Oakes director, officer: Chief Executive Officer 760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226
Patrick Truesdell officer: Vice President and Controller C/O LANDOS BIOPHARMA, INC., 1800 KRAFT DRIVE, SUITE 216, BLACKBURG VA 24060
Roger Adsett director 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Josep Bassaganya-riera director, 10 percent owner, officer: Chairman, President and CEO 1800 KRAFT DRIVE, SUITE 100, BLACKSBURG VA 24060
Patricia L Bitar officer: Interim CFO C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, STE 700, SAN DIEGO CA 92122
Perceptive Xontogeny Venture Fund, Lp director C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Xontogeny, Llc director 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Fred Callori director 100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110
Joseph Edelman director C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd director C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003